Biohacking Biotechs, page-8

I don't agree....speculative is more akin to whether the product under investigation/research/development is going to prove viable and non inferior...in CardioCel case, it is not only non inferior but is clearly superior to the other products and is on the way to being gold standard of many tissue defect repairs..so it is not a spec but an emerging biotech in the same position as Sirtex/Cochlear in the early days. I would not even put Resmed in the same category as its technology is only non inferior to its competitors..